Quick Overview
- Q1 adjusted EPS came in at $0.99, below the anticipated $1.05
- Annual EPS forecast reduced to $4.80–$5.00 from previous $4.95–$5.15 range
- Quarterly revenue reached $5.13 billion, surpassing $5.03 billion expectations
- Shares declined approximately 9% during premarket hours
- Organizational restructuring merges top two divisions into $14.6 billion business unit
GE HealthCare delivered underwhelming first-quarter results and reduced its annual profit projections, triggering a significant selloff in premarket activity on Wednesday.
The medical technology firm reported adjusted earnings of $0.99 per share, falling short of analyst expectations of $1.05. However, the top-line picture looked brighter — quarterly revenues totaled $5.13 billion, representing a 7.4% increase from the same period last year and beating the consensus estimate of $5.03 billion.
Operating margins stood at 13.5%, approximately one percentage point below what analysts had forecast.
Shares plummeted roughly 9.6% in early trading to around $61.93, extending what has already been a challenging year. The stock had declined 16% year-to-date before Wednesday’s announcement.
GE HealthCare Technologies Inc., GEHC
Chief Executive Peter Arduini attributed the lowered guidance to escalating expense pressures. The company faced higher costs for memory semiconductors, petroleum products, and transportation services throughout the quarter. Arduini noted that the organization anticipates mitigating more than 50% of these inflationary headwinds through strategic pricing adjustments and cost-reduction initiatives.
The full-year adjusted earnings outlook was reduced to a range of $4.80–$5.00 per share, down from the previous projection of $4.95–$5.15. The Street consensus had been calling for $5.06. Management maintained its organic revenue growth target of 3% to 4%.
New orders increased 1.1% during the first quarter, while comparable revenue grew 2.9%.
Major Organizational Realignment
GE HealthCare revealed plans to consolidate its two primary business divisions — imaging and advanced visualization solutions — into one unified segment dubbed Advanced Imaging Solutions, which will command a combined revenue base of $14.6 billion.
Phil Rackliffe, formerly leading the advanced visualization solutions division, will oversee the newly integrated segment. Roland Rott, who previously managed the imaging unit, will depart from the organization.
The restructuring aims to build a more integrated imaging platform and unlock operational synergies, according to company officials.
Catherine Estrampes, who has spent 35 years with the organization, was appointed Chief Commercial and Growth Officer and will oversee a new global markets division encompassing all territories outside China.
Underperforming Former GE Siblings
GEHC has struggled compared to its two counterparts that emerged from the historic General Electric breakup. Since spinning off in January 2023, the medical equipment manufacturer’s shares have gained just 13%, underperforming the S&P 500 by more than 70 percentage points during that timeframe.
Meanwhile, GE Aerospace has soared over 110% since the conglomerate’s division in April 2024. GE Vernova has been the clear winner, skyrocketing more than 675% over the identical period.
GE Aerospace has capitalized on robust aircraft engine demand. GE Vernova has benefited from the surge in power infrastructure investment. GE HealthCare, conversely, has contended with a more challenging landscape — weak demand trends, tariff uncertainties, and ongoing inflationary pressures.
The medical technology company does maintain a record order backlog approaching $22 billion entering 2026, which executives have highlighted as a platform for future expansion.
Heading into Wednesday’s earnings release, GEHC shares had risen only 1% over the trailing twelve months.
